57 citations · 57 across the 4 of their papers we have counts for
5 papers
Sharing information across patient subgroups to draw conclusions from sparse treatment networks
Theodoros Evrenoglou, Silvia Metelli, Johannes-Schneider Thomas +4
Network meta-analysis (NMA) usually provides estimates of the relative effects with the highest possible precision. However, sparse networks with few available studies and limited…
Improving clinical trial interpretation with ACCEPT analyses
Michelle N. Clements, Ian R. White, Andrew J. Copas +7
Effective decision making from randomised controlled clinical trials relies on robust interpretation of the numerical results. However, the language we use to describe clinical tri…
Handling an uncertain control group event risk in non-inferiority trials: non-inferiority frontiers and the power-stabilising transformation
Matteo Quartagno, A. Sarah Walker, Abdel G. Babiker +4
Background. Non-inferiority (NI) trials are increasingly used to evaluate new treatments expected to have secondary advantages over standard of care, but similar efficacy on the pr…
Between-trial heterogeneity in meta-analyses may be partially explained by reported design characteristics
Kirsty Rhodes, Rebecca Turner, Jelena Savović +3
Objective: We investigated the associations between risk of bias judgments from Cochrane reviews for sequence generation, allocation concealment and blinding and between-trial hete…
MultiBUGS: A parallel implementation of the BUGS modelling framework for faster Bayesian inference
Robert J. B. Goudie, Rebecca M. Turner, Daniela De Angelis +1
MultiBUGS (https://www.multibugs.org) is a new version of the general-purpose Bayesian modelling software BUGS that implements a generic algorithm for parallelising Markov chain Mo…